ESPR — Esperion Therapeutics Share News
0.000.00%
Last trade - 00:00- $822.04m
- $1.21bn
- $403.14m
Esperion Therapeutics Q4 revenue jumps 144% on US product strength
Brief: Esperion Therapeutics And Corstasis Therapeutics Announce Esperion’S Definitive Agreement To Acquire Corstasis, Expanding Its Cardiovascular Franchise With Enbumyst™ (Bumetanide Nasal Spray)
Brief: Esperion Therapeutics And Corstasis Therapeutics Announce Esperion’S Definitive Agreement To Acquire Corstasis, Expanding Its Cardiovascular Franchise With Enbumyst™ (Bumetanide Nasal Spray)
Brief: Esperion Reports $156 To $160 Million In Preliminary Full-Year 2025 U.S. Net Product Sales
Brief: Esperion Announces Inducement Grants Under Nasdaq Listing Rule
U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Dell
U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Kohl's
U.S. STOCKS ON THE MOVE-Coinbase, Best Buy, Abercrombie & Fitch
U.S. STOCKS ON THE MOVE-Alibaba, Spotify, Alphabet
Esperion gains after Piper Sandler initiates with 'overweight' rating
U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale Capital
U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, Alphabet
Esperion rises as partner launches cholesterol drug in Japan
U.S. STOCKS ON THE MOVE-Intuit, IES Holding, Workday
Esperion rises as partner launches cholesterol drug in Japan
Brief: Esperion Partner Otsuka Launches Nexletol In Japan
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease
Esperion Q3 revenue up 69% on prescription volumes